This page provides educational publications on Woulgan, its ingredients and its mode of action, in the form of scientific articles, posters or presentations for you. It will be updated regularly.
Webinar about stalled wound healing and bioactive beta-glucan
Presented by Journal of Wound Care (JWC) and Woulgan, 2017
Module 1: “Understand why wounds stall and what happens at a molecular level”
Module 2: “Discover how macrophages in stalled wounds can be activated by stimulation with Bioactive BetaGlucan, restarting the healing process”
Narrated by Brenda King, nurse consultant in tissue viability from the UK, this short 2-module, CPD-accredited webinar will give you a unique insight into how beta-glucan can re-start stalled wound healing.
Scientific Article: “A clinical evaluation of Woulgan® Biogel in the management of non-infected diabetic foot ulcerations”
Donna Welch, 2017
“Despite optimum treatment, some diabetic foot ulcers remain hard to heal. Diabetic foot ulcer progression may be delayed due to altered neutrophil function and dysfunctional macrophages with respect to the production of cytokines and growth factors essential for wound healing. Woulgan Biogel® is a sterile gel consisting of water, glycerol, carboxymethylcellulose and soluble beta-glucan (SBG). SBG stimulates Macrophages and can accelerate healing. Two case studies were completed to evaluate the effectiveness of Woulgan Biogel in managing non-infected chronic diabetic foot ulcers. Both case studies demonstrated positive patient outcomes with the ulcers healing completely. Woulgan Biogel was found to be an effective dressing and appeared to promote healing of previously static diabetic foot ulcers.”
Scientific Article: “Clinical evaluation of a bioactive beta-glucan gel in the treatment of ‘hard-to-heal’ wounds”
King et al, 2017
“The aim of this evaluation is to assess the effects of a wound healing gel in wounds of different aetiologies. Data was recorded on the wound surface area, tissue type, and patient level of wound pain at baseline (0) and at weeks 1, 2, 3, 4, and 8. Of the total 39 patients enrolled in the study, 26 patients who complied with the protocol criteria completed the minimum four-week study period. During the 12-week evaluation period, seven of the 26 wounds fully healed and an additional eight wounds showed a reduction in size of more than 50 %. Of the remaining 11, five wounds showed moderate healing progression and six wounds did not respond to treatment. Following the 12 week evaluation time point clinicians reported that a further three wounds healed—a 38 % healing rate”
Scientific Article: “Macrophage stimulating agent soluble yeast β‐1,3/1,6‐glucan as a topical treatment of diabetic foot and leg ulcers: A randomized, double blind, placebo‐controlled phase II study”
“β‐Glucans are potent inducers of immune function. The present randomized, double blind, two‐center, placebo‐controlled study was undertaken to explore safety, tolerability and efficacy of soluble β‐1,3/1,6‐glucan (SBG) as a local treatment of diabetic foot ulcers. A total of 60 patients with type 1 or 2 diabetes and lower extremity ulcers (Wagner grade 1–2, Ankle/Brachial Index ≥0.7) received SBG or a comparator product (methylcellulose) locally three times weekly up to 12 weeks in addition to conventional management scheme. A total of 54 patients completed the study.”
Scientific Paper: “Can the activation of the body’s own key cells in wound healing, WOUND MACROPHAGES, make a positive contribution in the treatment of chronic wounds?”
Skjæveland & Engstad, 2013
“A moist wound healing environment has for long been recognized as the principle for optimal healing in the treatment of wounds. Hence there are many products in the market that cater to this principle, both in terms of pure hydrogels and dressings containing moisturizing agents. Despite a huge range of products to choose from in the field of wound treatment, there is still a need for new and better products to treat complex, chronic wounds that do not heal or heal very slowly. This has resulted in the research and development of active products that not only safeguard the principles of moist wound healing, but which can also directly expedite the actual wound healing process.”
Scientific Paper: “Inflammation in chronic wounds – better than its reputation?”
Skjæveland & Grønvoll, 2017
When wound healing stalls it’s usually in the inflammatory phase, either because of a prolonged inflammation or an insufficient inflammatory response. This has lead to the general misconception that the inflammation phase is unnecessary and problematic in wound healing, especially for chronic wound conditions. This paper explains how the inflammation and proliferation phases are regulated at molecular level by macrophages and how you now can manipulate macrophage function clincally with beta-glucan stimulation. The paper is in Norwegian and was published in the december 2016 edition of “SÅR”.
Oral Presentation at NIFS – Annual Meeting of the Norwegian Wound Care Society, Fornebu 2015
“The activation of macrophages leads to positive results in the treatment of chronic wounds in a Norwegian study”
Skjæveland & Gerdts, 2015
The results of 55 patients with stalled wounds were presented, of which a majority had wounds older than several months, up until over a year old, and most of them were either diabetic foot, pressure or leg ulcers. 89% of the health care professionals involved in the evaluation stated that they wanted to continue the use of Woulgan Bioactive Beta-Glucan Gel.
(Note: The presentation is in Norwegian)
Wounds UK 2016 E-Posters
At the Wounds UK conference in Harrogate 2016, 6 e-posters describing Woulgan and its mode of action were presented. You can access them by clicking on their titles below.
“Health economics of a bioactive beta-glucan gel” by Keith F Cutting, Clinical Research Consultant, Hertfordshire, UK.
“The nature of beta-glucans – and the role in wound care of a novel bioactive beta-glucan gel: Woulgan” by Keith F Cutting, Clinical Research Consultant, Hertfordshire, UK.
“Two case studies to demonstrate the use of an innovative soluble beta-glucan product for the treatment of stalled wounds” by Lynne Hepworth, TVN from South West Yorkshire Foundation Trust.
“A clinical evaluation of Woulgan in the management of non-infected diabetic foot ulcerations” by Donna Welch, Advanced Podiatrist – Diabetes, Humber NHS Foundation Trust.
“The clinical and patient experience of using a bioactive beta-glucan gel on a hard-to-heal wound” by Ruth Fitzgerald, Tissue Viability Clinical Nurse Specialist, Royal Berkshire NHS Foundation Trust.
“The use of Woulgan to heal a chronic leg ulceration” by Jo Overfield, Tissue Viability Nurse, Humber NHS Foundation Trust.
EWMA 2016 E-Posters
The following three e-posters related to Woulgan describe the preparation of a wound bed, clinical outcomes and cost-effectiveness, and the role of beta-glucans in wound care.
These posters have first been presented at EWMA 2016 in Bremen, Germany, by Keith Cutting. We are glad that we can now also make the posters available to you.
To access the different posters, just click on one of the title images below!
Poster for Nordic Diabetic Foot Symposium 2016
The poster below was developed by Keith Cutting and presented at the Nordic Diabetic Foot Symposium 2016 in Copenhagen, Denmark. It describes the general mode of action of Woulgan Bioactive Beta-Glucan Gel and shows examples of 7 patients where the use of Woulgan led to the healing of stalled wounds.
Wounds UK 2014 Poster
The poster below was created by Heather Joy et al. for Wounds UK 2014 in Harrogate, England. It describes a study of 16 patients with venous leg ulcers who were treated with Woulgan Bioactive Beta-Glucan Gel. The researchers confirmed the effectiveness of Woulgan as a topical treatment for chronic wounds.
Blog posts on stalled wound healing
If you’re interested in reading more about stalled wound healing, soluble beta-glucan and macrophages, you can have a look at our past blog posts below:
If you have any questions, don’t hesitate to contact us!